FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327811777> ?p ?o ?g. }

• W4327811777 endingPage "2391" @default.
• W4327811777 startingPage "2380" @default.
• W4327811777 abstract "Most people with Multiple Sclerosis (pwMS) are subjected to immunomodulatory disease-modifying treatments (DMTs). As a result, immune responses to COVID-19 vaccinations could be compromised. There are few data on cellular immune responses to the use of COVID-19 vaccine boosters in pwMS under a broad spectrum of DMTs.In this prospective study, we analysed cellular immune responses to SARS-CoV-2 mRNA booster vaccinations in 159 pwMS with DMT, including: ocrelizumab, rituximab, fingolimod, alemtuzumab, dimethyl fumarate, glatiramer acetate, teriflunomide, natalizumab and cladribine.DMTs, and particularly fingolimod, interact with cellular responses to COVID-19 vaccination. One booster dose does not increase cellular immunity any more than two doses, except in the cases of natalizumab and cladribine. SARS-CoV-2 infection combined with two doses of vaccine resulted in a greater cellular immune response, but this was not observed after supplementary booster jabs. Ocrelizumab-treated pwMS who had previously received fingolimod did not develop cellular immunity, even after receiving a booster. The time after MS diagnosis and disability status negatively correlated with cellular immunity in ocrelizumab-treated pwMS in a booster dose cohort.After two doses of SARS-CoV-2 vaccination, a high response yield was achieved, except in patients who had received fingolimod. The effects of fingolimod on cellular immunity persisted for more than 2 years after a change to ocrelizumab (which, in contrast, conserved cellular immunity). Our results confirmed the need to find alternative protective measures for fingolimod-treated people and to consider the possible failure to provide protection against SARS-CoV-2 when switching from fingolimod to ocrelizumab." @default.
• W4327811777 created "2023-03-19" @default.
• W4327811777 creator A5009921505 @default.
• W4327811777 creator A5027481638 @default.
• W4327811777 creator A5032281372 @default.
• W4327811777 creator A5042781691 @default.
• W4327811777 creator A5049450042 @default.
• W4327811777 creator A5054352482 @default.
• W4327811777 creator A5058659649 @default.
• W4327811777 creator A5075497872 @default.
• W4327811777 creator A5076733232 @default.
• W4327811777 creator A5078760892 @default.
• W4327811777 creator A5088367256 @default.
• W4327811777 date "2023-03-18" @default.
• W4327811777 modified "2023-10-14" @default.
• W4327811777 title "A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies" @default.
• W4327811777 cites W2777074421 @default.
• W4327811777 cites W2886566407 @default.
• W4327811777 cites W3015217122 @default.
• W4327811777 cites W3042183476 @default.
• W4327811777 cites W3121831652 @default.
• W4327811777 cites W3123967880 @default.
• W4327811777 cites W3177039632 @default.
• W4327811777 cites W3189759436 @default.
• W4327811777 cites W3193480463 @default.
• W4327811777 cites W3198831432 @default.
• W4327811777 cites W3199930610 @default.
• W4327811777 cites W3200136047 @default.
• W4327811777 cites W3200343502 @default.
• W4327811777 cites W3205913119 @default.
• W4327811777 cites W3210620197 @default.
• W4327811777 cites W3212744212 @default.
• W4327811777 cites W3214434979 @default.
• W4327811777 cites W4200573823 @default.
• W4327811777 cites W4210493562 @default.
• W4327811777 cites W4211176076 @default.
• W4327811777 cites W4214879309 @default.
• W4327811777 cites W4220847911 @default.
• W4327811777 cites W4220886379 @default.
• W4327811777 cites W4224993583 @default.
• W4327811777 cites W4225121126 @default.
• W4327811777 cites W4281476562 @default.
• W4327811777 cites W4282005604 @default.
• W4327811777 cites W4282825850 @default.
• W4327811777 cites W4283395367 @default.
• W4327811777 cites W4285391027 @default.
• W4327811777 cites W4285724887 @default.
• W4327811777 cites W4286636768 @default.
• W4327811777 cites W4308102106 @default.
• W4327811777 cites W4310828373 @default.
• W4327811777 cites W4311707413 @default.
• W4327811777 cites W4313317420 @default.
• W4327811777 doi "https://doi.org/10.1007/s00415-023-11575-8" @default.
• W4327811777 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36933032" @default.
• W4327811777 hasPublicationYear "2023" @default.
• W4327811777 type Work @default.
• W4327811777 citedByCount "7" @default.
• W4327811777 countsByYear W43278117772023 @default.
• W4327811777 crossrefType "journal-article" @default.
• W4327811777 hasAuthorship W4327811777A5009921505 @default.
• W4327811777 hasAuthorship W4327811777A5027481638 @default.
• W4327811777 hasAuthorship W4327811777A5032281372 @default.
• W4327811777 hasAuthorship W4327811777A5042781691 @default.
• W4327811777 hasAuthorship W4327811777A5049450042 @default.
• W4327811777 hasAuthorship W4327811777A5054352482 @default.
• W4327811777 hasAuthorship W4327811777A5058659649 @default.
• W4327811777 hasAuthorship W4327811777A5075497872 @default.
• W4327811777 hasAuthorship W4327811777A5076733232 @default.
• W4327811777 hasAuthorship W4327811777A5078760892 @default.
• W4327811777 hasAuthorship W4327811777A5088367256 @default.
• W4327811777 hasBestOaLocation W43278117771 @default.
• W4327811777 hasConcept C12590561 @default.
• W4327811777 hasConcept C159654299 @default.
• W4327811777 hasConcept C203014093 @default.
• W4327811777 hasConcept C22070199 @default.
• W4327811777 hasConcept C2776036978 @default.
• W4327811777 hasConcept C2777703276 @default.
• W4327811777 hasConcept C2778577042 @default.
• W4327811777 hasConcept C2778843634 @default.
• W4327811777 hasConcept C2779015954 @default.
• W4327811777 hasConcept C2780640218 @default.
• W4327811777 hasConcept C2780653079 @default.
• W4327811777 hasConcept C2780801004 @default.
• W4327811777 hasConcept C2781004633 @default.
• W4327811777 hasConcept C3017875465 @default.
• W4327811777 hasConcept C71924100 @default.
• W4327811777 hasConcept C8891405 @default.
• W4327811777 hasConceptScore W4327811777C12590561 @default.
• W4327811777 hasConceptScore W4327811777C159654299 @default.
• W4327811777 hasConceptScore W4327811777C203014093 @default.
• W4327811777 hasConceptScore W4327811777C22070199 @default.
• W4327811777 hasConceptScore W4327811777C2776036978 @default.
• W4327811777 hasConceptScore W4327811777C2777703276 @default.
• W4327811777 hasConceptScore W4327811777C2778577042 @default.
• W4327811777 hasConceptScore W4327811777C2778843634 @default.
• W4327811777 hasConceptScore W4327811777C2779015954 @default.
• W4327811777 hasConceptScore W4327811777C2780640218 @default.
• W4327811777 hasConceptScore W4327811777C2780653079 @default.

• next